CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Dec. 14, 2011--
CardioNet, Inc. (NASDAQ:BEAT), a leading wireless medical technology
company with a current focus on the diagnosis and monitoring of cardiac
arrhythmias, today announced the launch of its next generation Mobile
Cardiac Outpatient Telemetry device.
Joseph Capper, President and Chief Executive Officer of CardioNet,
commented: “The launch of this state-of-the-art system is further
evidence of our commitment to advancing cardiac monitoring solutions to
meet the evolving needs of physicians and their patients. The
introduction of this new device enhances our leadership position in
cardiac monitoring with capabilities to improve the patient experience
and reduce costs. The new device will enable physicians to offer the
product in their offices, shortening the time to patient activation. The
monitor also incorporates instructional video which, combined with the
recent launch of an online tutorial, will further improve the patient
experience. The cost to manufacture this product is approximately
one-third less compared to our current system. Additionally, the
product’s flexible design will facilitate the seamless introduction of
planned future enhancements.”
About CardioNet
CardioNet is a leading provider of ambulatory, continuous, real-time
outpatient management solutions for monitoring relevant and timely
clinical information regarding an individual’s health. CardioNet’s
initial efforts are focused on the diagnosis and monitoring of cardiac
arrhythmias, or heart rhythm disorders, with a solution that it markets
as Mobile Cardiac Outpatient TelemetryTM (MCOTTM).
More information can be found at http://www.cardionet.com.
Forward-Looking Statements
This document includes certain forward-looking statements within the
meaning of the “Safe Harbor” provisions of the Private Securities
Litigation Reform Act of 1995 regarding, among other things, our growth
prospects, the prospects for our products and our confidence in the
Company’s future. These statements may be identified by words such as
“expect,” “may,” “anticipate,” “possible,” “estimate,” “potential,”
“intend,” “plan,” “believe,” “forecast,” “promises” and other words and
terms of similar meaning. Such forward-looking statements are based on
current expectations and involve inherent risks and uncertainties,
including important factors that could delay, divert, or change any of
them, and could cause actual outcomes and results to differ materially
from current expectations. These factors include, among other things,
effectiveness of our efforts to address operational initiatives,
including cost savings initiatives that affect our business, changes to
insurance coverage, relationships with our government and commercial
payors and reimbursement levels for our products, the success of our
sales and marketing initiatives, our ability to attract and retain
talented executive management and sales personnel, our ability to
identify acquisition candidates, acquire them on attractive terms and
integrate their operations into our business, the commercialization of
new products, market factors, internal research and development
initiatives, partnered research and development initiatives, competitive
product development, changes in governmental regulations and
legislation, the continued consolidation of payors, acceptance of our
new products and services and patent protection, adverse regulatory
action and litigation success. For further details and a discussion of
these and other risks and uncertainties, please see our public filings
with the Securities and Exchange Commission, including our latest
periodic reports on Form 10-K and 10-Q. We undertake no obligation to
publicly update any forward-looking statement, whether as a result of
new information, future events, or otherwise.
Source: CardioNet, Inc.
CardioNet, Inc.
Heather C. Getz
Investor Relations
800-908-7103
investorrelations@cardionet.com
